The Lucerne startup Altoida has secured funding from Eisai Innovation, as was reported in a press release. It is a strategic investment subsidiary of Japanese pharma group Eisai. The investment amount has not been disclosed.
Altoida and Eisai will continue to collaborate on research in future as well. This will help drive forward the solution for the early identification of Alzheimer’s disease. The development is based on augmented reality and artificial intelligence. Users complete a set of digital and augmented reality activities on their smartphone or tablet. This collects a range of diagnostic digital biomarkers for Alzheimer’s disease, which are analyzed using artificial intelligence. Doctors then use these results to predict the potential risk.
“The work Altoida is doing with digital biomarkers may prove to revolutionize how we approach dementias, including Alzheimer’s disease,” said Kazumasa Nagayama, Chief Strategy Officer at Eisai. This innovation helps identify patients in need of therapy earlier and enables interventions “years ahead of traditional methods”.